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O R I G I N A L
A R T I C L E
Association Between Sonographic Fatty Liver
and Ischemic Electrocardiogram Among 
Non-obese Taiwanese Male Adults
Yu-Cheng Lin, Jong-Dar Chen*
Background: Several overlapping risk factors exist between fatty liver and ischemic heart
disease (IHD). However, the epidemiologic association of fatty liver with IHD still awaits
assessment among non-obese adult subjects. We conducted this analysis by utilizing rou-
tine health examination data to evaluate the prevalence of fatty liver as well as IHD and
the epidemiologic relationship between fatty liver and IHD among non-obese Taiwanese
male adults.
Patients and Methods: After excluding obese subjects, periodic health examination data of
835 non-obese males were used for the final analysis. The health examination included
general medical evaluations, biochemical blood tests, an abdominal sonographic exami-
nation and a resting electrocardiogram (ECG). IHD was defined based on the evidence of
resting ECG ischemic changes, as expressed in computerized Minnesota code. Insulin resist-
ance was calculated by the equation of homeostasis model assessment (HOMAIR) and was
defined as the top quartile of HOMAIR for the total population. Student’s t and χ2 tests
and multivariate logistic regression were utilized to examine the relationship between IHD
and the potential risk factors. Data analyses were controlled for confounders such as liver
impairment, insulin resistance, dyslipidemia and hyperglycemia, which are the components
of metabolic syndrome.
Results: Mean age for this sample population was 37.6 years and body mass index (BMI) 
was 23.0kg/m2. Overall prevalence of sonographic fatty liver (SFL) was 19.0% (mild, 13.5%;
moderate to severe, 5.5%). Prevalence of ischemic changes in the resting ECG was 15.5%;
insulin resistance and metabolic syndrome were, respectively, 15.2% and 4.8%. The means
of BMI, levels of triglyceride, high-density lipoprotein (HDL) cholesterol, insulin and HOMAIR
in the two subgroups with SFL, mild or moderate to severe, were significantly more unfa-
vorable than in subjects without SFL. Prevalence rates for ischemic ECG, overweight,
abnormal liver function, insulin resistance, hypertriglyceridemia and hypo-HDL choles-
terolemia were all significantly higher in the two subgroups with SFL in contrast to the
SFL-free subjects. Increasing fatty liver severity was independently associated with an
increasing risk of IHD. After controlling for age, liver function test results and metabolic syn-
drome risk factors, mild SFL had a 1.8-fold (95% confidence interval [CI], 1.071–3.082)
and moderate to severe SFL had a 2.5-fold (95% CI, 1.071–3.082) increased risk of IHD.
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Introduction
Fatty liver is prevalent in developing and devel-
oped societies among both obese and non-obese
adults [1,2]. Most investigations of fatty liver have
focused on obesity [3,4], while for non-obese adult
Taiwanese, epidemiologic research on fatty liver is
lacking.
Moreover, many recent studies reported that
there are several overlapping risk factors such as
insulin resistance, dyslipidemia and hyperglycemia
[4–6] existing between fatty liver and cardiovascular
diseases [7–11]. Imaging and histologic studies have
indicated the independent associations between
fatty liver and cardiovascular abnormalities including
carotid arteriosclerosis [11–13], myocardial insulin
resistance [14] as well as endothelium dysfunction
[15–17]. However, in contrast to the evidence for
cardiovascular structural changes, there has been
little discussion on the electrocardiographic pres-
entation of non-obese subjects with fatty liver,
especially after controlling for confounders such as
insulin resistance and conventional risk factors.
There are two noninvasive examinations, the
abdominal sonogram and electrocardiogram (ECG),
included within many routine health checkups in
Taiwan. Abdominal sonogram examination is a
reliable tool for evaluation of fatty change of liver
[18,19] and computerized ECG [20] demonstrated
the diagnostic or predictive [21,22] values for
ischemic heart disease (IHD) in many large-scale
epidemiologic studies [23–27]. We conducted this
analysis by utilizing routine health examination data
from workers in a machinery maintaining factory to
evaluate the epidemiology of sonographic fatty liver
(SFL) and IHD among this non-obese, early middle-
aged Taiwanese male population and the relationship
between SFL and IHD. Data analyses were controlled
for the confounders of liver impairment and meta-
bolic syndrome components including insulin resist-
ance, dyslipidemia and hyperglycemia [28].
Patients and Methods
Subjects
Most workers of this machinery maintaining factory
are residents of north Taiwan, aged from 20 to 
65 years. The workplace is free from hazards of shift-
ing work or organic solvents exposure. The exclusion
criteria of our study were: body mass index (BMI)
> 27 kg/m2, waist circumference > 90 cm, fasting
glucose > 126 mg/dL or on any diabetes medical
treatment. The records of 835 non-obese male
workers from a periodic health examination between
July and September 2004 were collected for the
final analysis.
Methods
The physical examination included measurement of
weight, height and blood pressure. The definition of
obesity was BMI > 27 kg/m2 or waist circumference
> 90 cm based on Taiwanese criteria [29]. Elevated
blood pressure was defined as systolic blood pressure
≥130mmHg or diastolic blood pressure ≥85mmHg
[30]. A questionnaire about medical history, includ-
ing smoking (current usage: yes vs. no), was com-
pleted by the examinees. Biochemical blood tests
Conclusion: The results of this study showed a statistically significant association between
SFL and IHD among non-obese male adults. In addition to being a conventional liver sta-
tus surveying equipment, sonogram evaluation for fatty change in liver provides valuable
information about IHD risk assessment among non-obese Taiwanese male adults.
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were conducted by Hitachi autoanalyzer model
7150 (Hitachi Corp., Tokyo, Japan), which included:
aspartate aminotransferase (AST), alanine amino-
transferase (ALT), fasting plasma glucose, fasting
insulin, levels of triglyceride, total cholesterol and
high-density lipoprotein (HDL) cholesterol. Impaired
liver function was defined as ALT > 40 U/mL. The
definitions of hyperglycemia, hypo-HDL choles-
terolemia and hypertriglyceridemia were: fasting
sugar ≥110mg/dL, HDL <40mg/dL and triglyceride
≥ 150 mg/dL based on ATPIII criteria [30]. Insulin
resistance was calculated by the equation of home-
ostasis model assessment, HOMAIR = fasting insulin
(U/mL) ×glucose (mmol/L)/22.5, and defined as the
top quartile [31] of HOMAIR for the total population
including obese and non-obese people (data not
shown in this report).
Abdominal sonographic examinations were per-
formed using convex-type real-time electronic scan-
ners (Toshiba SSA-340 with 3.75-MHz convex-type
transducer) by three gastrointestinal physicians who
were blinded to the examinees’ medical history and
laboratory test results. The definition of SFL was
based on a comparative assessment of image bright-
ness in contrast to the kidneys, following previously
reported diagnostic criteria [18,19,32,33]. The
severity of SFL was classified according to the fol-
lowing modified scoring system [32–35]: bright-
ness compared with kidneys (0–3 points); blurring
of gallbladder wall (0–3 points); blurring of hepatic
veins (0–3 points); blurring of portal vein (0–3
points); and far gain attenuation (0–3 points). SFL
severity was defined as: mild (total score, 2–6
points), moderate (7–10 points) or severe (11–15
points).
A digital electrocardiograph recorder (Kenz
Cardico 1207; Suzuken Co., Nagoya, Japan) was
used for IHD assessment. IHD was defined based
on the evidence of resting ECG ischemic abnormal-
ities, as expressed in computerized Minnesota code
(1.1.×~1.3.×, 4.1.× ~4.4.×, 5.1.× ~5.3.×) [20–22].
Student’s t and χ2 tests were used for analyzing
continuous and categorical variables. Multivariate
logistic regression was utilized to examine the
association between IHD and potential risk factors.
SAS version 8.0 (SAS Institute, Cary, NC, USA) was
used for all statistical analyses.
Results
The characteristics of the patients are shown in
Table 1 and the prevalence rates of abnormality or
risk factors are in Table 2. The mean age for this pop-
ulation was 37.6 years; BMI, 23.0 kg/m2; fasting
sugar, 97.8 mg/dL; HDL cholesterol, 50.8 mg/dL;
triglyceride, 130.2mg/dL; fasting insulin, 7.1U/L and
HOMAIR, 1.7. The overall prevalence of fatty liver was
19.0% (mild, 13.5%; moderate to severe, 5.5%),
while the prevalence of ischemic changes in resting
ECG was 15.5%. Insulin resistance and the meta-
bolic syndrome were 15.2% and 4.8%, respectively.
Prevalence rates of the metabolic syndrome compo-
nents were elevated blood pressure, 40.1%; elevated
fasting sugar, 7.3%; elevated triglyceride, 25.6%;
and hypo-HDL cholesterolemia, 14.1%.
The risk factor distribution and the prevalence
rates of abnormality or risk factors among the three
subgroups stratified according to severity of SFL are
also presented in Tables 1 and 2. By grouping of
without, mild, and moderate to severe SFL, the
means of BMI (22.7, 23.8 and 24.4 kg/m2), waist
circumference (83.0, 85.2 and 85.8 cm), insulin
level (6.6, 8.7 and 10.7U/dL), HOMAIR (1.6, 2.1 and
2.6), triglyceride (119.3, 161.0 and 215.3 mg/dL)
and HDL cholesterol (51.7, 47.6 and 45.0 mg/dL)
were significantly unfavorable in the two subgroups
with SFL in contrast to the subjects without SFL. The
prevalence rates of ischemic ECG (13.6%, 21.2% and
28.3%), overweight (29.8%, 46.0% and 71.7%),
abnormal liver function (9.6%, 15.9% and 39.1%),
insulin resistance (11.2%, 28.3% and 41.3%), hyper-
triglyceridemia (21.6%, 39.0% and 52.2%) and
hypo-HDL cholesterolemia (12.4%, 20.4% and
24.0%) were all significantly higher in the two SFL
subgroups compared with the SFL-free subjects.
After controlling for liver function test results
and the two major risk factors for IHD, age and
smoking status, mild SFL had a 1.8-fold (95% con-
fidence interval [CI], 1.07–3.1) and moderate to
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severe SFL had a 2.5-fold (95% CI, 1.07–3.08)
increased risk of IHD (Fig.). Independent of liver
function test results, sonographic fatty change of
liver increases the risk of IHD. Overweight, insulin
resistance and metabolic syndrome could not be
demonstrated to have a statistically significant asso-
ciation with IHD from the present analysis for our
non-obese male adults.
Discussion
With the support of evidence from epidemiologic
studies and from the viewpoints of ethics and acces-
sibility, the noninvasive abdominal sonographic
examination [19,32,33] and the resting ECG [23–27]
demonstrate satisfactory reliability and are practical
tools to evaluate liver fatty change and heart ischemia.
Table 1. f f fBaseline data and distribution o  characteristics according to the severity o  sonographic atty liver (SFL)*
Characteristic
Without SFL Mild SFL Moderate to severe SFL Total
(n = 676; 81.0%) (n = 113; 13.5%) (n = 46; 5.5%) (n = 835)
Age (yr) 37.2 ± 9.7 39.2 ± 9.9† 39.4 ± 8.7 37.6 ± 9.7
BMI (kg/m2) 22.7 ± 2.0 23.8 ± 1.7† 24.4 ± 1.4† 23.0 ± 2.0
Waist circumference (cm) 83.0 ± 4.8 85.2 ± 3.8† 85.8 ± 2.9† 83.4 ± 4.6
Systolic blood pressure (mmHg) 124.7 ± 13.9 124.8 ± 15.1 128.7 ± 16.6 124.9 ± 14.3
Diastolic blood pressure (mmHg) 76.8 ± 9.7 76.6 ± 10.6 80.0 ± 11.8† 76.9 ± 10.0
Fasting sugar (mg/dL) 97.4 ± 8.0 98.5 ± 9.3 101.4 ± 9.0† 97.8 ± 8.3
Insulin (U/mL) 6.6 ± 3.8 8.7 ± 3.4† 10.7 ± 4.9† 7.1 ± 4.0
HOMAIR 1.6 ± 1.0 2.1 ± 0.9† 2.6 ± 1.2† 1.7 ± 1.0
AST (U/mL) 23.8 ± 11.8 24.2 ± 7.3 31.7 ± 16.1† 24.3 ± 11.7
ALT (U/mL) 24.5 ± 19.2 28.5 ± 13.4 46.6 ± 36.5† 26.3 ± 20.5
Triglyceride (mg/dL) 119.3 ± 87.7 161.0 ± 135.4† 215.3 ± 193.8† 130.2 ± 106.5
HDL-cholesterol (mg/dL) 51.7 ± 11.9 47.6 ± 8.8† 45.0 ± 8.4† 50.8 ± 11.5
*Data are presented as mean ± standard deviation; †p < 0.05 vs. group without SFL. BMI = body mass index; HOMAIR = yinsulin resistance assessed b
homeostasis model assessment; AST = aspartate aminotransferase; ALT = alanine aminotransferase; HDL = high-density lipoprotein.
Table 2. l f b l f k f f h l l d f h b l f dPreva ence rates o  a norma ity o  ris  actors or t e tota  popu ation an  or t e su groups c assi ie
by the severity of sonographic fatty liver (SFL)*
Abnormality/risk factor
Without SFL Mild SFL Moderate to severe SFL Total
(n = 676; 81.0%) (n = 113; 13.5%) (n = 46; 5.5%) (n = 835)
ECG with ischemic change 92 (13.6) 24 (21.2)† 13 (28.3)† 129 (15.5)
Overweight‡ 201 (29.7) 52 (46.0)† 33 (71.7)† 286 (34.3)
Elevated liver function§ 65 (9.6) 18 (15.9)† 18 (39.1)† 101 (12.1)
Insulin resistance|| 76 (11.2) 32 (28.3)† 19 (41.3)† 127 (15.2)
Elevated blood pressure¶ 262 (38.8) 49 (43.4) 24 (52.2) 335 (40.1)
Elevated fasting sugar¶ 41 (6.1) 12 (10.6) 8 (17.4)† 61 (7.3)
Elevated triglyceride¶ 146 (21.6) 44 (38.9)† 24 (52.2)† 214 (25.6)
Hypo-HDL cholesterolemia¶ 84 (12.4) 23 (20.4)† 11 (23.9)† 118 (14.1)
Metabolic syndrome¶ 25 (3.7) 8 (7.1) 7 (15.2)† 40 (4.8)
Currently smoking 240 (35.5) 35 (31.0) 17 (37.0) 292 (35.0)
*Data are presented as n (%); †p < 0.05 vs. group without SFL; ‡body mass index > 24 kg/m2; §aspartate/alanine aminotransferase > 40 mg/dL;
||homeostasis model assessment values in the top quartile; ¶ATPIII metabolic syndrome criteria. ECG = electrocardiogram; HDL = high-density lipoprotein.
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However, there are several limitations in our
study. The majority of our participants were early
middle-aged (mean age, 37.6 years) and we
excluded obese subjects. Thus, this study obtained
lower prevalence rates of fatty liver and IHD than
other observations [7,28]. At the same time, because
of the exclusion of obese subjects, the impact of
obesity closely related risk factors such as meta-
bolic syndrome and insulin resistance on IHD may
be underestimated in the present study (Fig.).
Compared with catheterization or stress test,
ischemic change on resting ECG is a weaker evi-
dence of IHD. For the reasons mentioned above,
the application of our conclusion to the general
population will be restricted.
Our SFL affected non-obese male adults had
higher prevalence rates of insulin resistance, liver
dysfunction and dyslipidemia compared with the
SFL-free subjects, similar to the conclusions of pre-
vious metabolic studies [29]. Furthermore, our results
indicate that non-obese male adults with SFL are
more likely to develop IHD compared with subjects
without SFL.
In previous biochemistry studies, fatty liver was
suggested to be a developer of the oxidative stress
that plays an important role in cardiac dysfunction
[36,37]. A previous study [38] of non-obese men
with fatty liver showed an increased systemic inflam-
matory response, which is an essential part of the
atherosclerotic process [39,40]. From the view-
point of molecular biology, hepatosteatosis and IHD
are both closely associated with the dysfunction of
mitochondria [41–43], which is the metabolic
energy producer, biosensor for oxidative stress and
the effector for cell death in liver or heart via the
apoptosis pathway [44,45]. Recent studies showed
that liver and heart uniquely share some mito-
chondrial enzymes [46] and microstructures [47].
Investigations of hepatosteatosis highlight that the
excess lipid peroxidation triggers mitochondrial
membrane permeabilization [48–50]. Vulnerable
or dysfunctional mitochondria play an important
role in myocardium apoptosis [51,52], and the
apoptosis of myocardium is likely to contribute to
a variety of heart conditions including ischemic
changes on ECG, which is the electrophysical 
presentation of myocardium death or injury [53].
Mitochondrial dysfunction may be a possible can-
didate linking hepatosteatosis and myocardium
ischemic damage.
The results of this study showed that there was
a statistically significant association between SFL
and IHD among non-obese male adults. In addi-
tion to being a conventional liver status surveying
equipment, sonogram evaluation for fatty change in
liver provides valuable information for IHD risk assess-
ment among non-obese Taiwanese male adults.
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